Clot microstructure as a marker of thrombogenicity in cancer
Research type
Research Study
Full title
FRACTAL DIMENSION (DF) AS A BIOMARKER OF THROMBOGENICITY IN CANCER ASSOCIATED THROMBOSIS.
IRAS ID
235294
Contact name
Simon Noble
Contact email
Sponsor organisation
Aneurin Bevan Health Board
Duration of Study in the UK
1 years, 11 months, 31 days
Research summary
The work will be a collaborative effort between Aneurin Bevan University Health Board, Velindre Cancer Centre and the HBRU (Swansea University/ABMU).The study will build on our previous work which demonstrated that this new blood test was able to identify differences in the blood of lung cancer compared to people without lung cancer. the test also showed that patients with more advanced lung cancer had the biggest change in their blood. In this new study we aim to explore this further with the new blood test. We aim to identify which lung cancer patients undergoing chemotherapy are at the highest risk of developing blood clots, a common problem in this group of patients. We aim to recruit 300 lung cancer patients undergoing chemotherapy. The results of the proposed study would be invaluable in predicting the risk some patients are at of developing clots which have a detrimental effect on the patient. The goal of the research is the development of a pragmatic risk assessment tool which may then be used to personalize and target treatment to benefit those most at risk, whilst decreasing the complications observed in patients who are not at the highest risk of developing clots.
REC name
Wales REC 5
REC reference
17/WA/0389
Date of REC Opinion
23 Mar 2018
REC opinion
Further Information Favourable Opinion